Harbour BioMed Reports P-III Trial Results of Batoclimab for the Treatment of Generalized Myasthenia Gravis
- The P-III clinical trial evaluates batoclimab (HBM9161), a fully human anti-FcRn mAb that blocks FcRn-IgG interactions in patients with gMG
- The trial met its 1EPs & 2EPs i.e., the therapy was found to be safe and well-tolerated & no new safety signal was observed while P-II study results showed that batoclimab can quickly and significantly alleviate patients’ symptoms and improve QoL
- In early 2021, Batoclimab received the Breakthrough Therapy Certificate from NMPA. Harbour BioMed & NBP Pharma collaborated to co-develop batoclimab in Great China & Harbour BioMed was responsible for developing & operating the full clinical trial of batoclimab for gMG in China
Ref: Harbour BioMed | Image: Harbour BioMed
Related Post:- Cullinan Oncology Entered into an Exclusive License with Harbour BioMed to Develop and Commercialize HBM7008 (CLN-418) in the US
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].